Thank you, Geoffroy, and hello, everyone. Let me start with safety, which is at the heart of everything we do.

Our transformation delivers tangible results with the reportable injury rate further improving in the second quarter, as you can see here. This positive development reflects the commitment of our teams.

We continue to strengthen our safety culture through targeted initiatives. For example, we now have a focus on hand injuries, slips, trips and falls and contractors' safety management.

So let's move to our performance. Our performance in the second quarter reflects different realities in an operating environment that is constantly evolving.

On the one hand, bicarbonate and electronic grade peroxides are at record sales levels. On the other hand, soda ash remains under competitive pressure in the export markets, indirectly weighing on the U.S.

market. On the conflict in the Middle East, we estimate that it had a negative impact of around EUR 20 million on the EBITDA in Q2.

The main element is the shutdown of the peroxides plant in Saudi Arabia. Outside of this, the impact is slightly negative with the improvement of the dynamics at Coatis not fully covering higher energy, raw materials and logistics costs.

Looking ahead, we currently anticipate that the peroxides plant in Saudi will restart in the second part of Q3. Our teams on site are working in this direction, and we will be ready as soon as the platform restarts.

I will come back to this when we talk about the outlook. Now 2 weeks ago, the European Union released its draft proposal for the reform of the Emissions Trading System.

Although it is too early still to fully assess the impact, we believe that this proposal moves in the right direction. Most importantly, it confirms the 2050 carbon neutrality objective while maintaining the allocation of free allowances.

The proposal appears significantly more focused on supporting industrial competitiveness and decarbonization rather than simply increasing costs of the European industry. We will continue to assess the proposal in the coming weeks.

As said, we believe it goes in the right direction, but there is still a lot of work to do before it is final. We will obviously update you on this topic in our next communications.

Now Alex, over to you for the details of the Q2 results.

Thank you, Philippe, and good morning, good afternoon, everyone. So let's move to the detail of the financial performance, which is mainly impacted by the continued weakness of the soda ash prices in export market, the conflict in the Middle East and the more general geopolitical environment.

Moving to Slide 9. And as usual, I will comment on the organic evolution, meaning at constant scope and currency, unless otherwise stated.

Underlying net sales in Q2 reached slightly over EUR 1 billion, down 7% compared to the second quarter of 2025, but up sequentially in all business units. The decline was mainly volume driven, reflecting the temporary shutdown of our peroxide plant in Jubail and the EUR 20 million one-off gain recorded in Q2 last year for the contract termination in the Fluorine business line.

Pricing was slightly lower overall, broadly stable across all our businesses, except for some pressure largely concentrated in the soda ash seaborne market. ForEx provided a small tailwind this quarter, thanks to the strengthening of the Brazilian real against the euro.

Now moving to EBITDA. We delivered an underlying EBITDA of EUR 187 million in the second quarter, down 20%, representing an EBITDA margin of 18.1%.

There are 2 main factors behind the year-on-year EBITDA decline, both explaining the significant volume drop of this quarter. Around half relates to the consequence of the conflict in the Middle East, mainly due to the temporary shutdown of our peroxide plant in Saudi.

The other half reflects the one-off in Special Chem in Q2 2025. Net pricing was broadly stable.

The improvement in Coatis was offset by higher costs in other businesses and continued pricing pressure in the soda ash export market. Fixed costs contributed positively as our structural cost saving initiatives more than offset inflation.

We delivered a further EUR 26 million of cost savings in the quarter, mainly through operational excellence initiatives in our manufacturing sites. Moving now to the segment review, starting with Basic Chemicals on Slide 10.

Sales in soda ash and derivatives declined by 8% organically. Soda ash volume were slightly lower year-on-year, partly because of some delayed shipments into July.

Pricing was marginally lower in domestic market and declined more significantly in the seaborne market. On the other hand, our bicarbonate business remained steady with both volumes and pricing broadly stable year-on-year.

Peroxide sales were down 5%. This mainly reflects the temporary shutdown of our HPPO plant in Saudi, which was partly offset by the continued strong growth in electronic grade supported by semiconductor demand.

Performance in other application was broadly stable. The segment EBITDA decreased by 6%.

Lower peroxide volumes and continued soda ash pricing pressure were partly mitigated by improved operational performance and cost discipline. Moving to Performance Chemicals on Slide 12.

Overall, Performance Chemicals EBITDA declined by 26%, mainly due to the absence of the EUR 20 million one-off benefit in Q2 2025 and a lag in price indexation in Silica. This was partly offset by a stronger performance in Coatis.

Looking at each business now. Silica sales were slightly down.

Overall performance remained solid after the quarter was affected by an unfavorable regional mix and a lag in price indexation. In our Coatis business, sales increased by 1% with improved pricing in both phenol and solvent product lines.

The difference between the year-on-year and organic performance mainly reflects the impact from the stronger Brazilian reais against the euro and the U.S. dollar.

This marks a clear sequential improvement for the Coatis business following the significant pressure experienced since the middle of the second quarter of last year. In Special Chem, sales declined by 18%.

The overall performance was stable in most business lines with a pickup of volume in electronic rare earth applications at quarter end. As highlighted before, the year-on-year comparison is primarily impacted by the contract termination benefit recorded in the second quarter of last year in our Fluorine business line.

Finally, a quick word on the corporate segment EBITDA, which was minus EUR 25 million in Q2. As expected, credit costs were still high during this quarter, reflecting the full impact of the exit of the TSC with Syensqo.

Based on this, I can confirm that our full year expectation remains between EUR 70 million and EUR 80 million. Turning to Slide 13.

Free cash flow to Solvay shareholders reached EUR 15 million in the first half of the year. The second quarter was negative at minus EUR 11 million due to the seasonality combined with some concentration of cash out, which I can explain as follows.

CapEx for the first half of the year represented approximately EUR 140 million. Spending remained disciplined and focused primarily on essential HSE and maintenance investment as well as ongoing energy transition project.

Working capital represented a cash outflow of minus EUR 79 million in the first half, reflecting the usual seasonality during the first 6 months of the year, including variable remuneration payments in Q2. Cash outflow from provisions amounted to EUR 106 million in the first half of the year.

As already explained, they are still some -- they are still above the normalized level and mainly relate to the transformation and restructuring initiatives. This includes the exit from the TSA, the optimization of the Fluorine business footprint and the remaining spending on the Dombasle energy transition project.

The free cash flow in the third quarter will remain under pressure from the above element, but we are firmly focused on delivering our full year free cash flow guidance. On Slide 14, let me remind you that our free cash flow in 2025, '26 and '27 is and will be impacted by temporary transformation expenses, which include the stranded cost linked to the exit of the TSA, the restructuring of the Fluorine business line and the development and implementation of a new ERP.

So looking at 2026, these expenses represent approximately EUR 90 million of cash outflow. We could improve cash generation by slowing or postponing our transformation.

But as already explained, we are convinced that continuing is the right direction, especially in this market condition. Moving now to net debt on Slide 15.

Underlying net debt stood at EUR 1.8 billion at the end of June, temporarily higher than at year-end, reflecting the full dividend payment in the first part of the year for EUR 254 million. Similarly, the leverage ratio temporarily increased above 2x at the end of the quarter and should be back around 2x at the end of the year.

This is consistent with the confirmation in June by S&P of our BBB- investment-grade rating. So overall, our Q2 results reflect the challenges brought by the conflict in the Middle East, which we need to manage while continuing the transformation of the group and maintaining a solid balance sheet.

Philippe, back to you for an update on the latest rare earth development and the 2026 outlook.

Thank you, Alex. Indeed, let me give you an update on our strategy regarding rare earth and the progress we are making in Nidacell.

With more than 75 years of experience in rare earth separation, Solvay holds a unique position globally. We are the only company outside of China with the technical know-how and industrial capabilities to separate all 17 rare earth elements, and that makes us a central player in the discussions around the setting up of rare earth value chains outside of China.

Operationally, we continue to accelerate our developments. To secure future feedstock supply, we recently signed a letter of intent with Viridis to source mixed light and heavy rare earth concentrates from Brazil with deliveries expected to start in 2028.

This agreement strengthens our long-term access to strategic raw materials and support our growth ambitions. The feedstock includes key rare earths for permanent magnets, notably Neodymium, Praseodymium which are called the light rare earth NdPr and dysprosium and terbium called DyTb, which are the heavy rare earth.

And this agreement supports the increasing global demand. It also contains an important distribution of additional heavy rare earth that I just mentioned used in critical advanced technology sectors such as automotive, electronics, medical and aerospace applications.

You remember, we reached an important milestone in April 2025 with the start of production of magnet light rare earth, so namely NdPr. This represented a first significant step in building a more integrated and diversified rare earth ecosystem in Europe.

Today, we are taking the next step by investing an additional EUR 15 million to EUR 20 million in heavy rare earth separation capabilities, creating additional opportunities in high-value applications. This includes the start of industrial scale production of DyTb in the fall of 2026.

Overall, these investments reinforce Solvay's leadership in rare earth, they strengthen European supply chain sovereignty and they position us to capture attractive growth opportunities in the energy transition and advanced technologies. So now moving to the outlook.

So today, we confirm our guidance for the year 2026. This guidance anticipates the restart of our peroxides plant in Saudi Arabia before the end of the third quarter.

More specifically, we confirm that we expect an underlying EBITDA between EUR 770 million and EUR 850 million, free cash flow to Solvay shareholders from continuing operations to exceed EUR 200 million with CapEx around EUR 300 million. So in conclusion, we remain fully committed to our essential chemistry strategy and to our transformation.

This is obviously challenging given the difficult environment we've been facing over the past few quarters. But however, we know it is essential to prepare Solvay for the future.

In our transformation, we do not forget growth. We remain highly selective and disciplined, investing in areas where we have differentiated capabilities and where we see compelling long-term demand growth.

This includes electronic grade of peroxides for which demand is booming due to AI and rare earth where there is a clear need to develop independent value chains, in particular for permanent magnets. Finally, we continuously evaluate the best possible way to create long-term value.

One way to do it is to review our portfolio of assets and businesses and assess whether there are opportunities to improve efficiency or reinforce it. This combination of transformation, disciplined growth and active footprint management is how we are building a stronger and more competitive Solvay for the future.

Thank you. And I think we're now happy to take your questions.

Geoffroy d'Oultremont Head of Investor Relations Yes. Thank you, Philippe and Alexandre.

So Gael, you can now open the line for questions, please.

Two questions, please. Firstly, could I ask your conviction on the Sadara peroxide restart and whether your decision today to hold the guidance is just simply a binary call on this restart mid-Q3 taking place or not or there are sort of other factors taking place?

I mean listening to Dow's conference call, they were saying the plant is still offline and it had suffered some damage. So I'm just wondering whether the communication you've heard was any different here?

And secondly, you noted that soda ash shipments were delayed from Q2 into July. Could you quantify the impact for us here?

Katie, thank you very much. What I can say very clearly regarding Sadara.

So just remember, we are producing hydrogen peroxide that we supply by pipe on the platform where we are 1 of 23 units. We are currently actively preparing this restart for -- before the end of the quarter.

And this is what basically we're getting prepared for. I think we're ready to restart.

That's what I can say, and this is what we assumed. Regarding soda ash, it's true that there has been a little bit of delay in some of the shipments from Q2 to Q3.

I don't know, Alex, you want to.

We cannot comment precisely. It's really a logistic question.

As you know, soda ash is exported, as you may know, it's exported by boat, so you quickly can get a big quantities if you have delayed a few shipments. In terms of top line, it's single-digit number of million of EBITDA.

What we mean, maybe to soda ash, what we mean is that on the annual basis, don't expect decrease or increase in volume. But one quarter to the other, you may have some phasing.

Yes. I have one question with, let's say, 3 sub-questions.

So you said that basically half of the EUR 40 million year-over-year EBITDA decrease in Q2 is due to lower peroxides volumes on the back of the Middle East conflict. I understand that roughly EUR 20 million earnings decline year-over-year is caused by the production stop of your HPPO plant in Sadara.

So when I know that this plant accounts for 2% to 2.5% of group sales and has the highest margin and do the math, then my questions are the following: A, is it fair to assume that this plant generated around 40% EBITDA margin 1 year ago; B, this plant is now heavily loss-making as you have costs, i.e., salaries, but you do not sell any products. And C, if there are losses right now, can you stop these losses of that plant in case the Middle East conflict lasts many years?

Okay. Thank you.

So basically, yes, I mean, we confirm that there is more or less a EUR 20 million impact of the Middle East crisis for us in Q2 and that the plant in Saudi Arabia represents a big part of it. So it's not the whole amount, but it's a big portion of it.

As you say, the plant has been idle since mid-March. And we lose the sales, and we also have some costs to incur.

Clearly, again, and I repeat, we are today preparing for a restart, right? And this restart is supposed to take place before the end of this quarter.

Now as you say, if the conflict continues, if that continues to have problems and so on, of course, there are a lot of different possible scenario. We will explore all of them and get back to you with the outcome of those discussions.

My first question was, I'm just looking at the soda ash prices, the future prices for soda ash in China is completely collapsed. It's now at lowest ever levels.

I think the contract price in Europe is $300. Soda ash prices in China are now $130, $140.

And I'm just curious, are you getting pressure from your customers in Europe who are using maybe imports from China as a reason to bring your prices down because I understand historically, it's not been as economical to ship soda ash from China to Europe. But given where the price differential sits today, I don't know if it starts to become actually economical.

And it just feels like this is the only one of the very few commodity products in chemicals where the Chinese exports into Europe really hasn't gone up that dramatically. And can that be a risk given the price delta now?

The second question was on your -- this announcement or this capacity expansion that you are doing for rare earth separation, it still seems pretty tiny to me. It's like EUR 15 million, EUR 20 million in the context of large expansions happening elsewhere in that space.

Firstly, can you confirm how much of that CapEx has been funded through by customer prepayments or subsidies or both? Or is this a net CapEx after some of these prepayments?

And second, like what do you still need to invest? I mean it feels like things are still progressing rather slowly with rare earth on Solvay side.

And the last question is, you typically have this EUR 15 million, EUR 20 million license income for HPPO. You didn't have it last year.

Did you have any in Q2? And if not, do you expect that to come through in H2?

And specifically when is it in Q3 or Q4?

Thank you, Chetan. So soda ash, I must confess that we're not looking too much about prices in China because we're not selling in China.

And for us, what is more important is the prices in the export market, so in Southeast Asia, Middle East, Africa and Latin America, and they're higher, obviously, than the domestic Chinese price. But still, you're right, they are at a very low level, historical low levels.

This is not new. And this, of course, has been taken into account in our outlook.

Does it put additional pressure in Europe? At this point, no.

I mean, because it's still very difficult to ship Chinese soda ash to Europe. We don't see any Chinese soda ash right now in Europe because the transport cost is extremely high.

And so our sites in Europe are still the best with the Turkish ones, obviously, in terms of cost to deliver in their domestic market. And that's really what matters.

However, it puts pressure on the volumes that are exported out of Europe and out of the U.S. This is why our seaborne business is currently not performing as well as it used to perform in the past years.

And it puts, by the way, also pressure on the U.S. producers because the U.S.

producers, including us, are exporting 50% of their capacity. And this is why you might have seen also that SBM has shut down its plant in California.

That's a direct consequence of what's happening on the seaborne market due to Chinese overcapacity. So it has consequences, but not directly, I would say, at this point on our European or U.S.

markets. Capacity expansion in rare earth, it might look small, but in reality, it's not.

I mean, remember that we are revamping an existing plant. We are repurposing units that already exist.

If you would have to do this type of investments outside of La Rochelle in any location in the world outside of China, it would cost 4, 5x more, right? So we really need to keep that in mind.

And this is why those investments are very interesting because they are built on an existing plant. And we are gradually building step by step a new value chain in this region.

You might have seen and I said that we've signed an agreement with Viridis to expand our options in terms of sourcing and we are indeed signing new contracts with customers for this new NdPr, DyTb and so on type of rare earth elements. These investments are done because we have the commitment of the customers.

This is why it's gradual, and we will move further with an objective in order to reach EUR 50 million to EUR 100 million of CapEx in the end. And they are also supported to some extent by the French government.

And they are also, in some cases, prefinanced by our customers. So all this make those investments possible and very promising.

Peroxide license, no, we don't have any revenue in Q2. We might have -- I mean, we're pursuing a certain number of opportunities.

But today, nothing is secured, but this is taken into account in our outlook, whatever happens.

Two, please, from my side. So on Coatis, the Brazilian expected tariff rate was recently increased to the U.S.

and Chinese exports in other chemical value chains are up in recent months. Does this make you less bullish on the prospect of recovery, sorry?

And on the ETS rule changes, does that change your need to make decarbonization investments on your European soda ash capacity through the end of the decade to compete with lower carbon Turkish soda ash? And could more funding be available from Europe to help you make the investments?

Thank you, Sebastien. So first question on Coatis.

A big part of the recovery is due to the current geopolitical context and the fact that -- and the consequences, I would say, of the conflict in the Middle East, the fact that the whole complex is going up and that pushes margin higher and so on and so forth and that the logistic routes are being disrupted. So that being said, a part of the recovery was also boosted by the end of the tariff.

That's true. It was not the main part, but it was a part was coming from that.

The previous tariff was 50%, plus 10%, I think, of baseline. Now we move to 25% plus 10%.

I think it's too early to say if it's going to have what type of impact it will have on our customers. We monitor this very carefully.

So far, we don't see any change in the order book. But of course, we monitor this extremely, extremely carefully.

But the new tariff is 50% of the previous one. So that we need to keep in mind.

The new ETS, I mean, first, it doesn't change anything on our ambition. Let's be clear.

Our ambition is to be carbon neutral by 2050. And we have a very clear trajectory in order to go there in the next 15 years.

So the new proposal is, in fact, in line with our ambition. This is where we're, I would say, comforted in our strategy is that the previous versions were too aggressive and putting us under pressure, the new version is in line, right?

So it doesn't mean that we will go slowly. It means that we will go as planned, okay?

That's what matters. Now will it create more opportunities?

I think that's the purpose because what we are asking for is indeed more support for the energy transition to redirect the revenues from the ETS more towards energy transition projects than in the past. And I think this is what is also planned in the new draft that has been proposed by the European Commission.

My first one is on the outlook as we move into '27 because I'm struggling to think about how earnings growth can materialize under certain circumstances. So on the one hand, we've got peroxides coming back.

On the other, I think Chetan alluded to, it's difficult to imagine scenarios where soda ash pricing is supportive in the year. I imagine Coatis might be down a little bit as well.

My point here is how exactly are you thinking about the prospects of achieving earnings growth in '27 and reconciling that with the fact that the dividend won't be covered in '26? And my second question is just on seasonality into Q3.

Is anything getting sequentially better or worse as we move from Q2 into Q3?

Thank you, Sebastian. So I will give the question on Q3 maybe to Alex.

In the meantime, just some elements regarding 2027. Clearly, I think it's very early to say anything about '27 at this point.

I mean we're, of course, focused on the delivering the 2026, and we just confirmed our guidance. And we are focused on what we control and what we control is our transformation.

And we are moving in the right direction. We are delivering the savings that we expect in our transformation, both on our side and at the group level.

And we are doing what we have to do also in terms of growth. We're not investing a lot of money, but we invest where we have to invest.

We mentioned electronic grade, CO2, rare earth, those are examples that will help us prepare the future and '27 in particular. Now on Q3, maybe Alex, I'll give you the floor.

Yes. And maybe also we have to make the transition.

And this is why we thought useful to show you the slide again with all our transformation expenses that we decided to maintain even if the economic context is challenging. We said this year, it should be around EUR 90 million and next year it should be in the tune of EUR 50 million.

So just this decision will improve the cash almost mechanically whatever the context by EUR 40 million and in terms of dividend, the Solvay dividend, I think it's an important piece of the equation. Now on the seasonality, if I think you're alluding to the seasonality probably of the cash, the cash, I mean, we expect really the cash to be back ended in Q4 because we will continue to spend quite a lot of money on this transformation cost, restructuring, ERP in Q3.

So the cash would tend to be quite back ended. What I want to make clear is that you see in H1 because the level of activity at the end of June was quite decent compared to a very low level at the end of December.

So we've invested in working cap close to EUR 80 million, and that will reduce in the second part of the year. But obviously, it's really when activity gets very low at the end of -- around November, December that we should see significant working capital decrease.

First, on your full year EBITDA guidance, it's still a relatively broad range. Could you explain a bit more about what need to happen to reach the upper end, midpoint and the lower end of the range?

And then same for the free cash flow guidance, what are the moving parts to get to above EUR 200 million? Is it really mainly the working capital unwind?

Or is there anything else? And then my other question is on the rare earth business.

I just wanted to understand the business a bit better. So maybe it would be helpful if you could quantify how large the rare earth business is today as a percentage of group sales or a percentage of Specialty Chemical sales.

And then I also wanted to ask on the customer offtakes, which -- what kind of customers are these? Are they from automotive industry, defense industry or what industry are they from?

And also, how are the agreements structured in terms of duration, committed volumes, pricing and also the flexibility to any of those elements?

Thank you, Julia. So maybe I will give you some elements on rare earth, and then I will give the floor to Alex on the range of the guidance on EBITDA for 2026.

So the size of the business at rare earth more or less half of Special Chem. It's 8% of the group sales.

Just to give you the order of magnitude of the size of the rare earth business. Historically, we've been delivering -- serving the markets of the auto catalysis and electronics and medical applications.

Now these new investments are related to permanent magnets. And indeed, permanent magnets are for electrification.

So you have all these type of customers that you mentioned: auto manufacturers, wind turbines, aerospace and so on and so forth that are looking for this type of material. And indeed, to invest, we need commitments from the customers because today, this market has been -- is mainly delivered from China and there are enough capacities in China.

So the type of commitments that we ask for and that we get in order to invest are volumes and prices through multiyear contracts to be simple. Alex, do you want to take the question on the EBITDA.?

Yes. So it will be quite simple.

I mean obviously, there are -- the volatility is the name of the game. I mean the same way we -- the situation changed dramatically in one direction with the Middle East crisis.

Can it move back in the other direction? Maybe.

I think today, what we've said is that the main impact is the HPPO plant being stopped. The rest between the Coatis, the cost of transport, the cost of energy, it's slightly negative, but manageable.

Can it turn positive? You have FX.

I mean, guess what, I mean there is not one specific element that needs to happen apart from the fact that, okay, we need to restart this HPPO unit and we are actively working on it to restart in the coming months and we're confident. Geoffroy d'Oultremont Head of Investor Relations I see, operator that we...

Thank you very much.

Thank you. Thank you.

Bye-bye.